Abstract
The emergence of SARS-CoV-2 Omicron variant (B.1.1.529) with major spike protein mutations has raised concern over potential neutralization escape and breakthrough infections among vaccinated and previously SARS-CoV-2 infected subjects. We measured cross-protective antibodies against variants in health care workers (HCW, n=20) and nursing home residents (n=9) from samples collected 1-2 months following the booster (3rd) dose. We also assessed the antibody responses in prior to Omicron era infected subjects (n=38) with subsequent administration of a single mRNA vaccine dose. Following booster vaccination HCWs had high IgG antibody concentrations to the spike protein and neutralizing antibodies (NAb) were detectable against all variants. IgG concentrations among the elderly remained lower, and some lacked NAbs against the Beta and Omicron variants. NAb titers were significantly reduced against Delta, Beta and Omicron compared to wild-type virus regardless of age. Vaccination induced high IgG concentrations and variable titers of cross-reactive NAbs in previously infected subjects, whereas NAb titers against Omicron were barely detectable 1-month post-infection. High IgG concentrations with cross-protective neutralizing activity were detected after three COVID-19 vaccine doses in HCWs. However, lower NAb titers seen in the frail elderly suggest inadequate protection against Omicron breakthrough infections, yet protection against severe COVID-19 is expected.
Clinical trial registration EudraCT 2021-004788-29
Competing Interest Statement
Finnish Institute for Health and Welfare has received research funding for unrelated studies from GlaxoSmithKline Vaccines (N.E., A.A.P. and M.M. as investigators), Pfizer (A.A.P.) and Sanofi Pasteur (A.A.P.). The other authors report no potential conflicts of interest.
Funding Statement
This study was funded by the Finnish institute for Health and Welfare and the Academy of Finland (Decision number 336431).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol of the COVID-19 vaccine immunological studies in Finland was approved by the National Committee on Medical Research Ethics (TUKIJA/347/2021) and by the Finnish Medicines Agency Fimea as the regulatory authority (European Union clinical trials database code of EudraCT 2021-004788-29). For the follow-up of COVID-19, the study protocol of the serological population study of the coronavirus epidemic was approved by the ethical committee of the Hospital District of Helsinki and Uusimaa (HUS/1137/2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data subject to third party restrictions. The data that support the findings of this study are available from Finnish Social and Health Data Permit Authority Findata. Restrictions apply to the availability of these data, which were used under license for this study under informed consent form. Anonymized data are available after permission by Findata.
Abbreviations
- BAU
- Binding antibody unit concentration
- COVID-19
- Coronavirus Disease 2019
- GMC
- Geometric mean concentration
- GMT
- Geometric mean titer
- HCW
- Health care worker
- MNT
- Microneutralization test
- mRNA
- Messenger ribonucleic acid
- NAb
- Neutralizing antibody
- RBD
- Receptor-binding domain
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SFL
- Full length spike glycoprotein
- anti-S IgG
- IgG antibodies to spike protein
- VE
- Vaccine effectiveness
- VOC
- Variants of concern
- WT
- Wild-type
